Perrigo Company plc shares climbed 4.6% in trading, a move that pushed the stock off recent lows even as its dividend yield remained perched above 7.7%: a level that first stood out in data tracked on Dividendly, a Madison Labs research site, which lists Perrigo's current yield at 7.96% against a quarterly payment of $0.29 per share, or $1.16 annualized.
The combination is unusual on its face: a stock jumping nearly five percent in a single session while still carrying one of the higher dividend yields among healthcare names typically points to a share price that has fallen far enough, or a payout that has grown fast enough, that the two figures now sit at odds with each other. Perrigo's 52-week range of $9.25 to $22.65 shows a stock that has traded in a wide band over the past year, and even after the day's gain, shares remain well below the top of that range.
What makes the yield figure notable to income-focused investors is what sits beneath it. Perrigo's trailing earnings per share is listed at -$10.29, a loss that renders the standard GAAP payout ratio, dividends as a share of earnings, not meaningful. When a company reports a net loss, the payout ratio calculation effectively breaks down, since there are no positive earnings against which to measure the dividend outlay. That leaves investors relying on other durability signals: Perrigo has raised its dividend for 22 consecutive years and has 23 years of payment history without a recorded cut, according to the tracked data. Those streaks speak to a long-run commitment to the payout, but they do not, on their own, resolve the earnings-coverage question raised by the negative EPS figure.
Why this matters to investors following Perrigo is straightforward: a dividend yield above 7.7% is high enough to draw attention on yield-screening tools, but yields that elevated often reflect a depressed share price rather than unusually generous dividend growth. Perrigo's market capitalization stands at $1.93 billion across 132.23 million shares outstanding, and the stock's day range of $14.07 to $15.00 shows meaningful intraday movement on volume of roughly 2.2 million shares. The company's most recent ex-dividend date was August 28, 2026, with the payment scheduled for September 15, 2026, meaning shareholders who held the stock through that date are positioned to receive the current distribution regardless of where the price moves next.
Perrigo, headquartered in Dublin and operating through its Consumer Self-Care Americas and Consumer Self-Care International segments, sells over-the-counter health and wellness products under brands including Compeed, Mederma, Prevacid24HR, and Opill, alongside contract manufacturing services. The company's business spans infant formula, digestive health, pain relief, and oral care categories, giving it exposure to consumer spending patterns across multiple geographies rather than a single therapeutic category tied to patent cycles, which is more typical of larger pharmaceutical peers.
The rally comes against a backdrop of sharp divergence within healthcare-adjacent names on the same trading day. Amgen fell 10.1%, Stryker dropped 8.8%, and Intuitive Surgical declined 4.5%, while Intel gained 9.1% and Advanced Micro Devices rose 5.9% in a broader market marked by outsized single-stock moves rather than a uniform sector trend. Perrigo's gain stands apart from the losses among several larger healthcare and medical device names on the same day, though the data provided does not indicate a shared cause behind the divergent moves.
What investors watching Perrigo are likely to track next includes whether the company's earnings trajectory turns positive in coming quarters, which would allow a conventional payout ratio to be calculated again, and whether the 22-year streak of dividend increases continues at the pace shown in the data's growth figures. The stock's rank score of 57 out of 100 in the tracked model (a screening measure blending yield, payout safety, growth, and momentum rather than a recommendation) falls short of the "Solid" threshold used in that framework, which requires a score of 70 or higher alongside a yield above 2%. Whether the day's price gain proves durable, and whether the elevated yield narrows through further share appreciation or instead reflects an ongoing valuation gap, remains to be seen in subsequent trading sessions.